Search

everythinglearnresearchcommunity

for

Search:↓

The conversation humorously discusses hair loss and treatments, specifically finasteride and topical minoxidil, with the OP joking about making art from shed hair. Users engage in light-hearted banter about hair loss and related habits.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The user regrets not using medication after a failed hair transplant and is now using a combination of minoxidil, finasteride, derma rolling, oils, and ketoconazole shampoo to try to improve hair regrowth. They are seeking feedback on progress and considering further treatment options.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The user shares their hair loss treatment routine, which includes topical minoxidil, botana oil, coconut moisturizer, derma stamping, derma rolling, 3% salicylic acid shampoo, and scalp massage. Suggestions include adding finasteride, switching to 2% ketoconazole shampoo, and using rosemary oil instead of botana oil.

A TikTok trend promoting a roll-on hair regrowth pen is discussed, with skepticism about its effectiveness without using finasteride or dutasteride. The original poster has been using finasteride for 2 years, minoxidil for 1 year, and microneedling for 12 months.

Using a dermaroller with topical minoxidil and oral finasteride regrows hair and improves temple areas. Users highlight the benefits of microneedling tools and stress the importance of consistency and proper sanitation.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

A user is experiencing temple hair recession and is seeking alternatives to finasteride. They are considering castor oil, coconut oil, and derma rolling, and have seen some improvement with Zenegen.

The conversation is about a user's comprehensive hair loss treatment plan, including finasteride, minoxidil, dermaroller, Nizoral shampoo, vitamin D, biotin, and zinc. The user describes their approach as a strategic battle against DHT, with finasteride as the main treatment.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

The user experienced hair growth improvement using a 1.25mm microneedle weekly, oral finasteride, oral minoxidil, and rosemary oil. They plan to switch to generic finasteride and minoxidil for safety concerns.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Microneedling is debated for hair loss treatment, with some users finding it beneficial for minoxidil absorption and others skeptical of its effectiveness. Alternatives like finasteride and minoxidil are recommended, while tools like dermarollers, dermapens, and dermastamps are discussed for their pros and cons.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The conversation discusses a person successfully using a combination of Minoxidil, finasteride, and other treatments for hair loss, resulting in significantly improved hair. Despite some criticism, many admire his dedication to health and anti-aging research.

The conversation discusses hair loss treatments, specifically using Minoxidil, finasteride, and RU58841. Users suggest simplifying the application routine and question the absence of dutasteride.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.